Marinus

Marinus Pharmaceuticals is a pharmaceutical company dedicated to developing innovative therapies for the treatment of rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors, acting on well-characterized targets in the brain known for their anticonvulsant, antidepressant, and anxiolytic effects. Ganaxolone is being developed in both intravenous and oral dosage forms, aiming to maximize the therapeutic reach in both acute and chronic care settings for adult and pediatric patient populations. Marinus is conducting the first-ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder, a Phase 2 trial in tuberous sclerosis complex, and a Phase 2 biomarker-driven proof-of-concept trial in PCDH19-related epilepsy. The company plans to initiate a Phase 3 trial in status epilepticus.